EGFR and non-small cell lung carcinoma: A meta-analysis of 26 studies demonstrated a positive association between EGFR-mutated NSCLC tumors and BMs, with an odds ratio (OR) of 1.58 (95% CI: 1.36–1.84), which confirms that EGFR mutation is a significant risk factor for BMs in NSCLC [60].